Bone marrow mesenchymal stromal cells support regeneration of intestinal damage in a colitis mouse model, independent of their CXCR4 expression.
Animals
Receptors, CXCR4
/ metabolism
Mesenchymal Stem Cells
/ metabolism
Colitis
/ chemically induced
Mesenchymal Stem Cell Transplantation
/ methods
Disease Models, Animal
Regeneration
Mice, Inbred C57BL
Mice
Dextran Sulfate
Intestinal Mucosa
/ metabolism
Chemokine CXCL12
/ metabolism
Bone Marrow Cells
/ metabolism
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
04
04
2024
received:
15
11
2023
accepted:
24
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is characterized by a chronically dysregulated immune response in the gastrointestinal tract. Bone marrow multipotent mesenchymal stromal cells have an important immunomodulatory function and support regeneration of inflamed tissue by secretion of soluble factors as well as through direct local differentiation. CXCR4 is the receptor for CXCL12 (SDF-1, stromal-derived factor-1) and has been shown to be the main chemokine receptor, required for homing of MSCs. Increased expression of CXCL12 by inflamed intestinal tissue causes constitutive inflammation by attracting lymphocytes but can also be used to direct MSCs to sites of injury/inflammation. Trypsin is typically used to dissociate MSCs into single-cell suspensions but has also been shown to digest surface CXCR4. Here, we assessed the regenerative effects of CXCR4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13821Subventions
Organisme : Hacettepe University Scientific Project Coordination Unit (BAP) project
ID : THD-2021-19634
Informations de copyright
© 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619‐1635.
Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. Dtsch Arztebl Int. 2016;113(5):72‐82.
Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021;8:765474.
Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther. 2013;137(3):283‐297.
Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297.
Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease. Gastroenterology. 2017;153(1):59‐62.e2.
Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61(3):468‐469.
Dhere T, Copland I, Garcia M, et al. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease ‐ a phase 1 trial with three doses. Aliment Pharmacol Ther. 2016;44(5):471‐481.
Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow‐derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12):1662‐1669.
Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109.
Pervin B, Aydın G, Visser T, Uçkan‐Çetinkaya D, Aerts‐Kaya FSF. CXCR4 expression by mesenchymal stromal cells is lost after use of enzymatic dissociation agents, but preserved by use of non‐enzymatic methods. Int J Hematol. 2021;113(1):5‐9.
Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF‐1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 2006;34(8):967‐975.
Liu X, Duan B, Cheng Z, et al. SDF‐1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell. 2011;2(10):845‐854.
Dotan I, Werner L, Vigodman S, et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis. 2010;16(4):583‐592.
Werner L, Guzner‐Gur H, Dotan I. Involvement of CXCR4/CXCR7/CXCL12 interactions in inflammatory bowel disease. Theranostics. 2013;3(1):40‐46.
Li X, Lan X, Zhao Y, et al. SDF‐1/CXCR4 axis enhances the immunomodulation of human endometrial regenerative cells in alleviating experimental colitis. Stem Cell Res Ther. 2019;10(1):204.
Heng BC, Cowan CM, Basu S. Comparison of enzymatic and non‐enzymatic means of dissociating adherent monolayers of mesenchymal stem cells. Biol Proced Online. 2009;11(1):161‐169.
Noronha NC et al. Priming approaches to improve the efficacy of mesenchymal stromal cell‐based therapies. Stem Cell Res Ther. 2019;10(1):131.
Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T‐cell proliferation and collagen‐induced arthritis. Arthritis Res Ther. 2010;12(1):R31.
van Til NP et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon‐optimized RAG2 therapeutic transgene. Mol Ther. 2012;20(10):1968‐1980.
Ulum B, Teker HT, Sarikaya A, et al. Bone marrow mesenchymal stem cell donors with a high body mass index display elevated endoplasmic reticulum stress and are functionally impaired. J Cell Physiol. 2018;233(11):8429‐8436.
Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Investig. 1993;69(2):238‐249.
Erben U, Loddenkemper C, Doerfel K, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7(8):4557‐4576.
Manea M, Mező G, Hudecz F, Przybylski M. Mass spectrometric identification of the trypsin cleavage pathway in lysyl‐proline containing oligotuftsin peptides. J Pept Sci. 2007;13(4):227‐236.
Simpson RJ. Fragmentation of protein using trypsin. CSH Protocols. 2006;2006:pdb.prot4550.
Kofuku Y, Yoshiura C, Ueda T, et al. Structural basis of the interaction between chemokine stromal cell‐derived factor‐1/CXCL12 and its G‐protein‐coupled receptor CXCR4. J Biol Chem. 2009;284(50):35240‐35250.
Brelot A, Heveker N, Montes M, Alizon M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem. 2000;275(31):23736‐23744.
Naheed F, Mumtaz R, Shabbir S, et al. Structural and phylogenetic analysis of CXCR4 protein reveals new insights into its role in emerging and Re‐emerging diseases in mammals. Vaccines (Basel). 2023;11(3):671.
Stephens BS, Ngo T, Kufareva I, Handel TM. Functional anatomy of the full‐length CXCR4‐CXCL12 complex systematically dissected by quantitative model‐guided mutagenesis. Sci Signal. 2020;13(640):eaay5024.
Zhou N, Luo Z, Luo J, et al. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV‐1 co‐receptor by mutagenesis and molecular modeling studies. J Biol Chem. 2001;276(46):42826‐42833.
Costa MJ, Kudaravalli J, Liu WH, Stock J, Kong S, Liu SH. A mouse model for evaluation of efficacy and concomitant toxicity of anti‐human CXCR4 therapeutics. PLoS One. 2018;13(3):e0194688.
Peng L, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF. Molecular basis for the antagonistic activity of an anti‐CXCR4 antibody. MAbs. 2016;8(1):163‐175.
Almutary AG, Alnuqaydan AM, Almatroodi SA, Tambuwala MM. Comparative analysis of the effect of different concentrations of dextran sodium sulfate on the severity and extent of inflammation in experimental ulcerative colitis. Appl Sci. 2023;13(5):3233.
Chassaing B, Aitken JD, Malleshappa M, Vijay‐Kumar M. Dextran sulfate sodium (DSS)‐induced colitis in mice. Curr Protoc Immunol. 2014;104:15.25.1‐15.25.14.
He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow‐derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57(12):3136‐3144.
Xie M, Qin H, Luo Q, et al. Comparison of adipose‐derived and bone marrow mesenchymal stromal cells in a murine model of Crohn's disease. Dig Dis Sci. 2017;62(1):115‐123.
Lee DS, Lee KL, Jeong JB, Shin S, Kim SH, Kim JW. Expression of chemokine CCL28 in ulcerative colitis patients. Gut and Liver. 2021;15(1):70‐76.
Martinez‐Fierro ML, Garza‐Veloz I, Rocha‐Pizaña MR, et al. Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease. Medicine. 2019;98(38):e17208.
Boshagh MA, Foroutan P, Moloudi MR, et al. ELR positive CXCL chemokines are highly expressed in an animal model of ulcerative colitis. J Inflamm Res. 2019;12:167‐174.
Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26‐42.
Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF‐1 and I‐TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203(9):2201‐2213.
Liu H, Liu S, Li Y, et al. The role of SDF‐1‐CXCR4/CXCR7 axis in the therapeutic effects of hypoxia‐preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One. 2012;7(4):e34608.
Shao Y, Zhou F, He D, Zhang L, Shen J. Overexpression of CXCR7 promotes mesenchymal stem cells to repair phosgene‐induced acute lung injury in rats. Biomed Pharmacother. 2019;109:1233‐1239.
Chen Z, Chen Q, du H, Xu L, Wan J. Mesenchymal stem cells and CXC chemokine receptor 4 overexpression improved the therapeutic effect on colitis via mucosa repair. Exp Ther Med. 2018;16(2):821‐829.
Nan Z, Fan H, Tang Q, et al. Dual expression of CXCR4 and IL‐35 enhances the therapeutic effects of BMSCs on TNBS‐induced colitis in rats through expansion of Tregs and suppression of Th17 cells. Biochem Biophys Res Commun. 2018;499(4):727‐734.
Zheng XB, He XW, Zhang LJ, et al. Bone marrow‐derived CXCR4‐overexpressing MSCs display increased homing to intestine and ameliorate colitis‐associated tumorigenesis in mice. Gastroenterol Rep (Oxf). 2019;7(2):127‐138.
Liu X, Zuo D, Fan H, et al. Over‐expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue. J Mol Histol. 2014;45(2):181‐193.
Fan H, Zhao G, Liu L, et al. Pre‐treatment with IL‐1β enhances the efficacy of MSC transplantation in DSS‐induced colitis. Cell Mol Immunol. 2012;9(6):473‐481.
Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010;5(1):121‐143.
Liu J, Lai X, Bao Y, et al. Intraperitoneally delivered mesenchymal stem cells alleviate experimental colitis through THBS1‐mediated induction of IL‐10‐competent regulatory B cells. Front Immunol. 2022;13:853894.
Sanchez‐Diaz M, Quiñones‐Vico MI, Sanabria de la Torre R, et al. Biodistribution of mesenchymal stromal cells after Administration in Animal Models and Humans: a systematic review. J Clin Med. 2021;10(13):2925.
Castelo‐Branco MTL, Soares IDP, Lopes DV, et al. Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and Ameliorate experimental colitis. PLoS One. 2012;7(3):e33360.
Cuesta‐Gomez N, Graham GJ, Campbell JDM. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J Transl Med. 2021;19(1):156.